Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer. Verathamjamras C, Sriwitool TE, Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Prasongsook N, Srisomsap C, Svasti J, Champattanachai V*. Glycoconj J. 2021 Feb;38(1):55-65.

01 Feb 2021
0

Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer.

Verathamjamras C, Sriwitool TE, Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Prasongsook N, Srisomsap C, Svasti J, Champattanachai V*.

Glycoconj J. 2021 Feb;38(1):55-65.

Tags

Share this

Related Posts

Thongdee, P.; Hanwarinroj, C.; Pakamwong, B.; Kamsri, P.; Punkvang, A.; Leanpolchareanchai, J.; Ketrat, S.; Saparpakorn, P.; Hannongbua, S.; Ariyachaokun, K.; Suttisintong, K.; Sureram, S.; Kittakoop, P.; Hongmanee, P.; Chanthammachat, P.; Mukamolova, G.; Blood, R.; Takebayashi, Y.; Spencer, J.; Mulholland, A,; Pungpo, P. Virtual Screening Identifies Novel and Potent Inhibitors of Mycobacterium tuberculosis PknB with Antibacterial Activity. J. Chem. Inf. Model. 2022, DOI: 10.4155/fmc-2022-0124

Recent Posts